S2 Cell culture
INS-1 (rat insulinoma cells), C2C12 (mouse myoblasts), and HepG2 (human hepatocarcinoma cells) (ATCC, Manassas, VA, USA) were used for the in vitro studies. They were cultured in RPMI-1640 (Gibco by Life Technologies, Carlsbad, CA, USA) or DMEM (Gibco by Life Technologies, Carlsbad, CA, USA) supplemented with different constituents as mentioned below. All cultured cell lines were maintained in an incubator at 37˚C containing humidified air of 5% CO2 at passages less than 25.
S3 Determination of insulin secretion and sensitivity, and glucose uptake in vitro
INS-1 cells were seeded at 2.5 × 10 5 cells per well into a 12-well plate (ThermoFisher Scientific, Waltham, MA USA) and cultured in RPMI-1640 (Gibco by Life Technologies, Carlsbad, CA, USA) containing 10% FBS (Gibco by Life Technologies, Carlsbad, CA, USA), 11 mM glucose, 1% penicillin/streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, and 50 µM 2-mercaptoethanol. After 72 h, cells were treated for 48h with metformin (750 µM) either alone or in combination with HCE (100 and 200 µg/mL) in KRBB-HEPES medium (134 mM NaCl, 4.8 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES, 1 mg/ml BSA, pH 7.4) supplemented with 11 mM glucose. Following this, the medium was discarded and replaced with high glucose (20 mM)-containing KRBB-HEPES medium and the cells were incubated in this condition for 1.5 h. Insulin concentration of the cell supernatant was quantified using a Mercodia ELISA Rat Insulin Kit (Mercodia, Uppsala, Sweden) according to the kit manufacturer's protocol. Immediately, the cells were lyzed in lysis buffer (1% Triton-X, 20 mM HEPES, pH 7.4, 100 mM KCl, 2 mM EDTA, 1.0 mM PMSF, with protease inhibitors (Roche, Mannheim, Germany). Total protein of the cell lysate was measured using a BCA assay kit (Thermo Scientific, Rockford, IL, USA). The level of secreted insulin was normalized to the total cellular protein content.
C2C12 myocytes and HepG2 cells were seeded at 1 × 10 4 cells per well into 96-well black, clear bottom plates (Greiner Bio-One, Frickenhausen, Germany) and cultured for 24 h in glucose-containing DMEM supplemented with 10% FBS. In case of C2C12 cells, the media was then discarded and replaced with glucose-containing DMEM supplemented with 2% horse serum. The C2C12 cells were incubated in this condition until differentiation of more than 90% of the cells was achieved (approximately 96 h). After 2 h wash out by FBS-free and glucose-free DMEM, HepG2 and differentiated C2C12 cells were treated with 10 mM glucosamine (Sigma-Aldrich, St. Louis, MO, USA) and/or 200 nM insulin (Eli Lilly and Company, Indianapolis, IN, USA) for 3 h. Finally, C2C12 and HepG2 cells were exposed to metformin (750 µM) either alone or in combination with HCE (50, 100 and 200 µg/mL) for 12 h followed by treatment with 75 µg/mL 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2-NBDG, Life Technologies, San Francisco, CA, USA) for 2 h. In glucose uptake assay, 50 µM apigenin was used as a negative control for comparison purpose. The uptake of 2-NBDG by the cells was detected by fluorescence microscopy (Olympus BX-61, Tokyo, Japan) and determined using a SpectraMax M3 fluorescence reader (Molecular Devices, Sunnyvale, CA, USA) with excitation and emission wavelengths at 475 and 515 nm, respectively. Figure S1 . Profile of body mass and glucose metabolism. Body weight of rats were recorded once per week (A). Fasting blood glucose (B) and serum insulin (C) were determined at the end of experimental schedule. (D) HOMA-insulin resistance was calculated as: [fasting blood insulin level (mg/dL) X fasting blood glucose level (ng/mL)]/405. Table S1 . Body weight, fat and organ weights, food intake and food efficiency ratio, and other parameters of the different experimental groups 
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